The stock of IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) is a huge mover today! About 836,839 shares traded hands or 62.28% up from the average. IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) has risen 33.96% since March 8, 2016 and is uptrending. It has outperformed by 24.65% the S&P500.
The move comes after 5 months negative chart setup for the $66.64 million company. It was reported on Oct, 11 by Barchart.com. We have $2.27 PT which if reached, will make NASDAQ:IPCI worth $9.33M less.
Analysts await IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) to report earnings on October, 14. They expect $-0.07 earnings per share, up 12.50% or $0.01 from last year’s $-0.08 per share. After $-0.08 actual earnings per share reported by IntelliPharmaCeutics Intl Inc (USA) for the previous quarter, Wall Street now forecasts -12.50% EPS growth.
According to Zacks Investment Research, “Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada.”
More news for IntelliPharmaCeutics Intl Inc (USA) (NASDAQ:IPCI) were recently published by: Benzinga.com, which released: “16 Stocks Moving In Monday’s Pre-Market Session” on October 10, 2016. Benzinga.com‘s article titled: “12 Biggest Mid-Day Losers For Tuesday” and published on October 11, 2016 is yet another important article.
IPCI Company Profile
Intellipharmaceutics International Inc., incorporated on October 22, 2009, is a pharmaceutical firm specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, the Company has developed several drug delivery systems and a pipeline of products and product candidates at various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix family of technologies includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle, Point of Divergence Drug Delivery System (nPODDDS) and Paradoxical OverDose Resistance Activating System (PODRAS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.